[ad_1]
San Diego, January 15, 2022 /PRNewswire/—— Robbins Geller Rudman & Dodd LLP Announced Talis Biomedical Corporation (NASDAQ:TLIS) common stock pursuant to and/or traceable to the registration statement and prospectus associated with Talis Biomedical (collectively, the “Registration Statement”) February 12, 2021 Initial public offering (“IPO”) until March 8, 2022 Seeking appointment as lead plaintiff Modrach v. Talis Biopharmaceuticals, No. 22-cv-00105 (ND Cal.).start with January 7, 2022 and pending before a judge Susan Ilston, This Biomedical Science The class action alleges that Talis Biomedical, certain of its officers and directors, and the underwriters of Talis Biomedical’s initial public offering violated the Securities Act of 1933.
If you have suffered a substantial loss and wish to be the lead plaintiff in this case Biomedical Science class action lawsuit Click here to provide your information. You can also contact a lawyer JC Sanchez Call 800/449-4900 or email Robbins Geller jsanchez@rgrdlaw.com. Lead Plaintiff’s Motion Biomedical Science A class action must be brought to court no later than March 8, 2022.
case allegations: Talis Biomedical purportedly develops diagnostic tests for accurate, reliable, low-cost and rapid molecular testing for infectious diseases and other diseases at the point of care. Talis One is developing tests for respiratory infections, women’s health-related infections and sexually transmitted infections. Through the IPO, Talis Biomedical sold more than 15.8 million shares of common stock for 15.8 million shares. $16.00 per share. The net proceeds received by Talis Biomedical are approximately $232.6 million from an initial public offering.
This Biomedical Science The class action alleges that the IPO’s registration statement…
The full story is available on Benzinga.com
[ad_2]
Source link
